HHS said Friday the company will use the funds to conduct large-scale production and Phase 3 trials of the experimental AZD7442 combo drug to help prevent or treat SARS-CoV-2 infections.
The biopharmaceutical firm licensed the two antibodies from Vanderbilt University and extended the compounds' duration of action using a proprietary technology.
According to HHS, the antiviral cocktail is intended to neutralize the novel coronavirus and reduce its ability to infect cells in the human body.
The federal government plans to widely distribute AZD7442 if the product receives approval from the Food and Drug Administration as part of Operation Warp Speed.
Client Solution Architects has appointed Ellen Barletto as chief growth officer, expanding her leadership responsibilities after nearly two decades with…
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
